Ranbaxy Laboratories ties-up with Zenotech to market cancer injectibles

Ranbaxy Laboratories Ltd has announced entering into a strategic alliance with Zenotech Laboratories Ltd (Zenotech), India. Under the semi-exclusive agreement, Ranbaxy will market Zenotech's oncology cytotoxic injectable products under its own label, leveraging its global marketing and distribution network, in the key markets of Latin America including Brazil and Mexico, and Russia and other CIS markets. Ranbaxy may also expand this collaboration to other markets. Zenotech will develop and manufacture these oncology products at their dedicated facilities located in India.

According to Peter Burema, president, Europe, Africa, CIS and Latin America, Ranbaxy, said, "We welcome this opportunity to join hands with Zenotech towards establishing a relationship that will complement each others strengths. The alliance facilitates Ranbaxy's entry into this new therapeutic segment in these key markets. Ranbaxy will continue to strengthen its product portfolio and provide novel products for the benefit of the patients."

Ranbaxy already has a presence in the oncology segment in India and sells its oncology products in the domestic market through its Super Specialties division.